+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Infliximab"

From
From
From
Ulcerative Colitis Market Report 2025 - Product Thumbnail Image

Ulcerative Colitis Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Arthritis Monoclonal Antibodies Market Report 2025 - Product Thumbnail Image

Arthritis Monoclonal Antibodies Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market Report 2025 - Product Thumbnail Image

Biosimilar Monoclonal Antibodies Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
TNF Alpha Inhibitors Market Report 2025 - Product Thumbnail Image

TNF Alpha Inhibitors Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Graft Versus Host Disease (GVHD) Treatment Market Report 2025 - Product Thumbnail Image

Graft Versus Host Disease (GVHD) Treatment Market Report 2025

  • Report
  • April 2025
  • 200 Pages
  • Global
From
Remicade Biosimilar Market Report 2025 - Product Thumbnail Image

Remicade Biosimilar Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Tumor Necrosis Factor Inhibitor Drugs Market Report 2025 - Product Thumbnail Image

Tumor Necrosis Factor Inhibitor Drugs Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
From
Psoriasis Market Report 2025 - Product Thumbnail Image

Psoriasis Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
From
From
From
Loading Indicator

Infliximab is a monoclonal antibody used to treat a variety of immune disorders, including Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis. It works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Infliximab is administered intravenously and is usually given in combination with other medications. It is also used to treat certain types of eye inflammation and to prevent organ rejection in transplant patients. Infliximab is a biologic drug, meaning it is derived from living cells. It is produced by a number of pharmaceutical companies, including Merck, Pfizer, and Janssen. It is available in both brand-name and generic forms. The companies in the Infliximab market include Merck, Pfizer, Janssen, Celltrion, Hospira, and Sandoz. Show Less Read more